Performance in Initiating - Q1: 2016/2017 (1st July 2015 - 30th June 2016) - non HRA studies

Research Ethics Committee Reference Number	IRAS number	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	Date of First Patient Recruited	Duration between VRA and First Patient	Benchmark Met	Comments	Reasons for delay correspond to:
15/LO/0413	171579	BEACON - Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration	17/08/2015	17/08/2015	17/09/2015	31	Yes	FP	Neither
14/NI/1120	149397	EDNA - Early detection of neovascular age-related macular degeneration	24/08/2015	03/09/2015	08/10/2015	45	Yes	FP	Neither
15/NE/0086	164686	CHROMA - Lampalizumab in Geographic Atrophy	02/09/2015	07/09/2015			No	FP	Neither
15/LO/0538	173212	SPRAINED - Synthesising a clinical Prognostic Rule for Ankle INjuries in the Emergency Department	01/09/2015	10/09/2015	22/09/2015	21	Yes	HWP	Neither
15/SW/0177	180522	PREMISE - A European PRospective Observational StudyAssessing the Effectiveness and Outcomes Associatedwith Enzalutamide Treatment in Patients withMetastatic Castration ResIstant ProState CancEr (mCRPC).	19/10/2015	28/10/2015	25/11/2015	37	Yes	HWP	Neither
15/LO/1166	178877	HARRIER - Efficacy and Safety of RTH258 versus Aflibercept	18/11/2015	19/11/2015	22/12/2015	34	Yes	FP	Neither
11/SS/0100	84669	FOCUS - The effect (s) of routine administration of Fluoxetine in patients with a recent stroke	22/12/2015	23/12/2015	28/01/2016	37	Yes	FP	Neither
15/LO/1637	186118	WATER: Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue	14/01/2016	15/01/2016	01/02/2016	18	Yes	FP	Neither
15/LO/1015	182526	AQUA: Open label Phase4 study to examine the change of vision related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment.	10/02/2016	12/02/2016	19/05/2016	99	No	FP - Difficult to recruit to	Neither
15/SC/0409	183061	SEQUOIA: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration	28/01/2016	02/02/2016	17/03/2016	49	Yes	FP	Neither
13/EE/0038	111368	HALT-IT: Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial	11/02/2016	15/02/2016	14/03/2016	32	Yes	FP	Neither

14/NE/1144	154101	NATTINA: The NAtional Trial of Tonsillectomy IN Adults: a clinical and cost effectiveness study	08/03/2016	10/03/2016	12/05/2016	65	Yes	FP	Neither
14/SS/1025	156908	SUPPORT HF2: Home monitoring with integrated riskstratified disease management support versus home monitoring alone in patients with heart failure: a randomised controlled trial	22/02/2016	10/03/2016	25/04/2016	63	Yes	HWP	Neither
14/SC/0171	120104	Add-Aspirin: A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours	21/03/2016	22/04/2016			No	FP. Submitted early due to HRA changeover requirements	Neither
15/EM/0437	184390	COLUMBUS: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration	21/03/2016	05/04/2016			No	FP. Submitted early due to HRA changeover requirements	Neither
15/NI/00243	191267	EMPIRE: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis	30/03/2016	08/04/2016			No	FP. No patients consented yet.	Neither